Changzhou Qianhong Biopharma CO.,LTD

Shenzhen Stock Exchange 002550.SZ

Changzhou Qianhong Biopharma CO.,LTD Shareholders' Equity for the year ending December 31, 2023: USD 345.78 M

Changzhou Qianhong Biopharma CO.,LTD Shareholders' Equity is USD 345.78 M for the year ending December 31, 2023, a -2.62% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Changzhou Qianhong Biopharma CO.,LTD Shareholders' Equity for the year ending December 31, 2022 was USD 355.08 M, a 6.06% change year over year.
Changzhou Qianhong Biopharma CO.,LTD Shareholders' Equity for the year ending December 31, 2021 was USD 334.79 M, a 5.06% change year over year.
Changzhou Qianhong Biopharma CO.,LTD Shareholders' Equity for the year ending December 31, 2020 was USD 318.65 M, a -4.84% change year over year.
Changzhou Qianhong Biopharma CO.,LTD Shareholders' Equity for the year ending December 31, 2019 was USD 334.86 M, a -8.96% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Shenzhen Stock Exchange: 002550.SZ

Changzhou Qianhong Biopharma CO.,LTD

CEO	Mr. Ke Wang
IPO Date	Feb. 18, 2011
Location	China
Headquarters	No. 90 Changjiang Middle Road
Employees	1,067
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Composite Materials Personal Care Pet Food Pharmaceuticals Plastics

Description

Changzhou Qianhong Biopharma CO.,LTD engages in the research and development, production, and sale of bio-pharmaceutical products with a focus on polysaccharides and enzymes in China. The company provides various API products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; kallidinogenase kallikrein for use in the treatment of microcirculation disorders; and heparinoid. It also offers a range of preparations, such as nadroparin calcium PFS, enoxaparin sodium PFS, dalteparin sodium PFS, and asparaginase and heparin sodium injections for use as anticoagulants. In addition, the company exports its products. Changzhou Qianhong Biopharma CO.,LTD was founded in 1971 and is headquartered in Changzhou, China.

Key trends

Past 5 years